Logo image of AKYA

AKOYA BIOSCIENCES INC (AKYA) Stock Fundamental Analysis

NASDAQ:AKYA - Nasdaq - US00974H1041 - Common Stock - Currency: USD

1.23  -0.03 (-2.38%)

After market: 1.23 0 (0%)

Fundamental Rating

1

AKYA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of AKYA have multiple concerns. AKYA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKYA has reported negative net income.
In the past year AKYA has reported a negative cash flow from operations.
AKYA had negative earnings in each of the past 5 years.
AKYA had a negative operating cash flow in each of the past 5 years.
AKYA Yearly Net Income VS EBIT VS OCF VS FCFAKYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

AKYA has a Return On Assets of -42.20%. This is amonst the worse of the industry: AKYA underperforms 80.00% of its industry peers.
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROIC N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
AKYA Yearly ROA, ROE, ROICAKYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

AKYA has a Gross Margin of 61.74%. This is amongst the best in the industry. AKYA outperforms 81.82% of its industry peers.
In the last couple of years the Gross Margin of AKYA has remained more or less at the same level.
AKYA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
AKYA Yearly Profit, Operating, Gross MarginsAKYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

0

2. Health

2.1 Basic Checks

AKYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
AKYA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AKYA has more shares outstanding
Compared to 1 year ago, AKYA has a worse debt to assets ratio.
AKYA Yearly Shares OutstandingAKYA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AKYA Yearly Total Debt VS Total AssetsAKYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

AKYA has an Altman-Z score of -4.25. This is a bad value and indicates that AKYA is not financially healthy and even has some risk of bankruptcy.
AKYA has a worse Altman-Z score (-4.25) than 89.09% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.25
ROIC/WACCN/A
WACC12.25%
AKYA Yearly LT Debt VS Equity VS FCFAKYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.61 indicates that AKYA may have some problems paying its short term obligations.
AKYA has a Current ratio of 0.61. This is amonst the worse of the industry: AKYA underperforms 98.18% of its industry peers.
A Quick Ratio of 0.40 indicates that AKYA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.40, AKYA is doing worse than 96.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.61
Quick Ratio 0.4
AKYA Yearly Current Assets VS Current LiabilitesAKYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

3

3. Growth

3.1 Past

AKYA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.69%, which is quite impressive.
AKYA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.55%.
Measured over the past years, AKYA shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%

3.2 Future

AKYA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.11% yearly.
Based on estimates for the next years, AKYA will show a small growth in Revenue. The Revenue will grow by 7.53% on average per year.
EPS Next Y42.36%
EPS Next 2Y24.76%
EPS Next 3Y16.59%
EPS Next 5Y11.11%
Revenue Next Year7.43%
Revenue Next 2Y9.5%
Revenue Next 3Y9.22%
Revenue Next 5Y7.53%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AKYA Yearly Revenue VS EstimatesAKYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
AKYA Yearly EPS VS EstimatesAKYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKYA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKYA Price Earnings VS Forward Price EarningsAKYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKYA Per share dataAKYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as AKYA's earnings are expected to grow with 16.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.76%
EPS Next 3Y16.59%

More info and screens

0

5. Dividend

5.1 Amount

AKYA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (6/13/2025, 8:00:00 PM)

After market: 1.23 0 (0%)

1.23

-0.03 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners34.48%
Inst Owner Change7.98%
Ins Owners4.15%
Ins Owner Change-1.51%
Market Cap61.35M
Analysts51.67
Price Target1.92 (56.1%)
Short Float %N/A
Short Ratio4.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.8%
Min EPS beat(2)-53.04%
Max EPS beat(2)-2.56%
EPS beat(4)1
Avg EPS beat(4)-13.87%
Min EPS beat(4)-53.04%
Max EPS beat(4)1.15%
EPS beat(8)3
Avg EPS beat(8)-8.79%
EPS beat(12)4
Avg EPS beat(12)-9.37%
EPS beat(16)5
Avg EPS beat(16)-10.77%
Revenue beat(2)0
Avg Revenue beat(2)-10.08%
Min Revenue beat(2)-18.23%
Max Revenue beat(2)-1.93%
Revenue beat(4)0
Avg Revenue beat(4)-12.79%
Min Revenue beat(4)-27.44%
Max Revenue beat(4)-1.93%
Revenue beat(8)3
Avg Revenue beat(8)-9.2%
Revenue beat(12)7
Avg Revenue beat(12)-5.07%
Revenue beat(16)10
Avg Revenue beat(16)-2.97%
PT rev (1m)-37.04%
PT rev (3m)-47.71%
EPS NQ rev (1m)-15.01%
EPS NQ rev (3m)-13.28%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.58%
Revenue NQ rev (1m)-3.18%
Revenue NQ rev (3m)-5.5%
Revenue NY rev (1m)-2.45%
Revenue NY rev (3m)-3.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS1.6
BVpS-0.12
TBVpS-0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.74%
FCFM N/A
ROA(3y)-39.84%
ROA(5y)-34.16%
ROE(3y)-322.43%
ROE(5y)-224.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.01%
GM growth 5Y0.08%
F-Score5
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25%
Cap/Sales 2.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.61
Quick Ratio 0.4
Altman-Z -4.25
F-Score5
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)58.71%
Cap/Depr(5y)73.75%
Cap/Sales(3y)5.54%
Cap/Sales(5y)6.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y42.36%
EPS Next 2Y24.76%
EPS Next 3Y16.59%
EPS Next 5Y11.11%
Revenue 1Y (TTM)-14.55%
Revenue growth 3Y14.14%
Revenue growth 5Y14.1%
Sales Q2Q%-9.32%
Revenue Next Year7.43%
Revenue Next 2Y9.5%
Revenue Next 3Y9.22%
Revenue Next 5Y7.53%
EBIT growth 1Y35.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.58%
EBIT Next 3Y7.24%
EBIT Next 5Y9.43%
FCF growth 1Y48.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.89%
OCF growth 3YN/A
OCF growth 5YN/A